Evidence map›Paper›PMID 22298889›Full record

ReviewOncotarget2012

Neoplastic cells are a rare component in human glioblastoma microvasculature.

Fausto J Rodriguez, Brent A Orr, Keith L Ligon, Charles G Eberhart

Open access · hybridAbstract readReview
In one paragraph

Review in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 85 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Three-DimensionalFrontiers in toxicology · 2021
    Review
  12. Tumor Endothelial Cell-A Biological Tool for Translational Cancer Research.International journal of molecular sciences · 2020
    Review
  13. Tumor angiogenesis: causes, consequences, challenges and opportunities.Cellular and molecular life sciences : CMLS · 2020
    Review
  14. Review
  15. Article
  16. Article
  17. Endothelial trans-differentiation in glioblastoma recurring after radiotherapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
  18. Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018
    Review
  19. Article
  20. Multiscale modeling of glioblastoma.Translational cancer research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Fausto J RodriguezDepartment of Pathology, Division of Neuropathology, Johns Hopkins University, MD, USA. frodrig4@jhmi.edu
Brent A Orr
Keith L Ligon
Charles G Eberhart
Johns Hopkins University · USDana-Farber Cancer Institute · US

Funding

TRAINING PROGRAM IN THE PATHOBIOLOGY OF CANCERT32CA067751 · NCI · JOHNS HOPKINS UNIVERSITY · PI GABRIELSON, EDWARD W. · 1996 to 2011
$4.0M
Notch signaling in brain tumorsR01NS055089 · NINDS · JOHNS HOPKINS UNIVERSITY · PI EBERHART, CHARLES G · 2007 to 2016
$3.2M
Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
NCI NIH HHS T32 CA067751NCI NIH HHS T32CA067751NCI NIH HHS T32 CA193145NINDS NIH HHS 5R01NS055089NINDS NIH HHS R01 NS055089
6 · The paper itself

Abstract

Microvascular proliferation is a key biological and diagnostic hallmark of human glioblastoma, one of the most aggressive forms of human cancer. It has recently been suggested that stem-like glioblastoma cells have the capacity to differentiate into functional endothelial cells, and that a significant proportion of the vascular lining in tumors has a neoplastic origin. In principle, this finding could significantly impact the efficacy and development of antiangiogenic therapies targeting the vasculature. While the potential of stem-like cancer cells to form endothelium in culture seems clear, in our clinical experience using a variety of molecular markers, neoplastic cells do not contribute significantly to the endothelial-lined vasculature of primary human glioblastoma. We sought to confirm this impression by analyzing vessels in glioblastoma previously examined using chromogenic in situ hybridization (CISH) for EGFR and immunohistochemistry for mutant IDH1. Vessels containing cells expressing these definitive neoplastic markers were identified in a small fraction of tumors, but only 10% of vessel profiles examined contained such cells and when identified these cells comprised less than 10% of the vascular cellularity in the cross section. Interestingly, these rare intravascular cells showing EGFR amplification by CISH or mutant IDH1 protein by immunohistochemistry were located in the middle or outer portions of vessel walls, but not amongst the morphologic boundaries of the endothelial lining. To more directly address the capacity of glioblastoma cells to contribute to the vascular endothelium, we performed double labeling (Immunofluorescence/FISH) for the endothelial marker CD34 and EGFR gene locus. This analysis did not identify EGFR amplified CD34+ endothelial cells within vascular linings, and further supports our observation that incorporation of glioblastoma cells into the tumor vessels is, at best, extremely rare of questionable clinical or therapeutic significance.

Indexed as

AnimalsAntigens, CD34Brain NeoplasmsCell CountEndothelium, VascularErbB ReceptorsGenes, erbB-1GlioblastomaHumansMicrovesselsNeoplastic Stem CellsNeovascularization, PathologicAntigens, CD34EGFR protein, humanErbB Receptors

Identifiers

PMID22298889
PMCPMC3292896
OpenAlexW2142578179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.